MESO
Mesoblast LimitedNASDAQHealthcare$14.81-6.27%ClosedMarket Cap: $1.91B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.26
P/S
121.49
EV/EBITDA
-39.06
DCF Value
$-2.73
FCF Yield
-3.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-218.7%
Operating Margin
-572.0%
Net Margin
-500.5%
ROE
-14.0%
ROA
-10.0%
ROIC
-12.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $7.0M | -231.1% | $-34.4M | $-27.1M | $-0.21 | — |
| FY 2025 | $17.2M | 70.2% | $-62.4M | $-102.1M | $-0.84 | — |
| Q3 2025 | $7.0M | -231.1% | $-34.4M | $-27.1M | $-0.21 | — |
| Q2 2025 | $1.6M | -107.8% | $-20.6M | $-24.0M | $-0.21 | — |
| Q1 2025 | $1.6M | -107.8% | $-20.6M | $-24.0M | $-0.21 | — |
| Q4 2024 | $1.3M | -762.3% | $-22.0M | $-27.7M | $-0.25 | — |
| FY 2024 | $5.9M | -595.9% | $-84.1M | $-88.0M | $-0.89 | — |
| Q3 2024 | $1.3M | -762.3% | $-22.0M | $-27.7M | $-0.25 | — |
| Q2 2024 | $1.7M | -472.4% | $-20.1M | $-16.3M | $-0.19 | — |
| Q1 2024 | $1.7M | -472.4% | $-20.1M | $-16.3M | $-0.19 | — |
| Q4 2023 | $2.1M | -620.9% | $-19.1M | $-21.9M | $-0.23 | — |
| FY 2023 | $7.5M | -632.2% | $-69.3M | $-81.9M | $-0.98 | — |